Pacific Biosciences of California Inc reports results for the quarter ended June 30 - Earnings Summary

• Pacific Biosciences of California Inc PACB.OQ reported a quarterly adjusted loss of 14 cents​​ per share for the quarter ended June 30, higher than the same quarter last year, when the company reported EPS of -64 cents. The mean expectation of thirteen analysts for the quarter was for a loss of 17 cents per share. Wall Street expected results to range from -20 cents to -14 cents per share.

• Revenue rose 10.4% to $39.77 million from a year ago; analysts expected $36.92 million.

• Pacific Biosciences of California Inc's reported EPS for the quarter was a loss of 14 cents​.

• The company reported a quarterly loss of $41.93 million.

• Pacific Biosciences of California Inc shares had risen by 11.3% this quarter and lost 24.6% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts had risen by about 4.5% in the last three months.​

• In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy," 8 "hold" and no "sell" or "strong sell." The average consensus recommendation for the advanced medical equipment & technology peer group is also "buy"

• Wall Street's median 12-month price target for Pacific Biosciences of California Inc is $1.80, about 30% above its last closing price of $1.26

This summary was machine generated from LSEG data August 8 at 04:20 a.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)